Refractive error outcomes after intravitreal ranibizumab for retinopathy of prematurity

REFERENCES

• Section on Ophthalmology; American Academy of Pediatrics; American Academy of Ophthalmology and; American Association for Pediatric Ophthalmology and Strabismus. Screening examination of premature infants for retinopathy of prematurity. Pediatrics 2006; 117: 572–576.
   PubMed Web of Science ®Google Scholar
• Gilbert C, Fielder A, Gordillo L et al. Characteristics of infants with severe retinopathy of prematurity in countries with low, moderate, and high levels of development: implications for screening programs. Pediatrics 2005; 115: e518–e525.
   PubMed Web of Science ®Google Scholar
• Early Treatment for Retinopathy of Prematurity Cooperative G. Revised indications for the treatment of retinopathy of prematurity: results of the early treatment for retinopathy of prematurity randomized trial. Arch Ophthalmol 2003; 121: 1684–1694.
   PubMed Web of Science ®Google Scholar
• Mintz‐hittner HA, Kennedy KA, Chuang AZ et al. Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity. N Engl J Med 2011; 364: 603–615.
   PubMed Web of Science ®Google Scholar
• Huang Q, Zhang Q, Fei P et al. Ranibizumab injection as primary treatment in patients with retinopathy of prematurity: anatomic outcomes and influencing factors. Ophthalmology 2017; 124: 1156–1164.
   Web of Science ®Google Scholar
• Harder BC, von Baltz S, Schlichtenbrede FC et al. Early refractive outcome after intravitreous bevacizumab for retinopathy of prematurity. Arch Ophthalmol 2012; 130: 800–801.
   Google Scholar
• Geloneck MM, Chuang AZ, Clark WL et al. Refractive outcomes following bevacizumab monotherapy compared with conventional laser treatment: a randomized clinical trial. JAMA Ophthalmol 2014; 132: 1327–1333.
   PubMed Web of Science ®Google Scholar
• Harder BC, Schlichtenbrede FC, von Baltz S et al. Intravitreal bevacizumab for retinopathy of prematurity: refractive error results. Am J Ophthalmol 2013; 155: 1119–1124, e1111.
   PubMed Web of Science ®Google Scholar
• Hittner HM, Rhodes LM, Mcpherson AR. Anterior segment abnormalities in cicatricial retinopathy of prematurity. Ophthalmology 1979; 86: 803–816.
   Web of Science ®Google Scholar
• Chen TC, Tsai TH, Shih YF et al. Long‐term evaluation of refractive status and optical components in eyes of children born prematurely. Invest Ophthalmol Vis Sci 2010; 51: 6140–6148.
   PubMed Web of Science ®Google Scholar
• Wang J, Ren X, Shen L et al. Development of refractive error in individual children with regressed retinopathy of prematurity. Invest Ophthalmol Vis Sci 2013; 54: 6018–6024.
   Web of Science ®Google Scholar
• Chen SN, Lian I, Hwang YC et al. Intravitreal anti‐vascular endothelial growth factor treatment for retinopathy of prematurity: comparison between Ranibizumab and Bevacizumab. Retina 2015; 35: 667–674.
   PubMed Web of Science ®Google Scholar
• Kabatas EU, Kurtul BE, Altiaylik ozer P et al. Comparison of Intravitreal Bevacizumab, Intravitreal Ranibizumab and laser photocoagulation for treatment of type 1 retinopathy of prematurity in Turkish preterm children. Curr Eye Res 2017; 42: 1054–1058.
   PubMed Web of Science ®Google Scholar
• Chen Y, Feng J, Gilbert C et al. Time at treatment of severe retinopathy of prematurity in China: recommendations for guidelines in more mature infants. PLoS One 2015; 10: e0116669.
   PubMed Web of Science ®Google Scholar
• International Committee for the Classification of Retinopathy of P. The international classification of retinopathy of prematurity revisited. Arch Ophthalmol 2005; 123: 991–999.
   PubMed Web of Science ®Google Scholar
• Namba H, Sugano A, Nishi K et al. Age‐related variations in corneal geometry and their association with astigmatism: the Yamagata study (Funagata). Medicine (Baltimore) 2018; 97: e12894.
   Web of Science ®Google Scholar
• Thibos LN, Wheeler W, Horner D. Power vectors: an application of Fourier analysis to the description and statistical analysis of refractive error. Optom Vis Sci 1997; 74: 367–375.
   PubMed Web of Science ®Google Scholar
• Blencowe H, Lawn JE, Vazquez T et al. Preterm‐associated visual impairment and estimates of retinopathy of prematurity at regional and global levels for 2010. Pediatr Res 2013; 74: 35–49.
   PubMed Web of Science ®Google Scholar
• Vanderveen DK, Melia M, Yang MB et al. Anti‐vascular endothelial growth factor therapy for primary treatment of type 1 retinopathy of prematurity: a report by the American Academy of ophthalmology. Ophthalmology 2017; 124: 619–633.
   Web of Science ®Google Scholar
• Lin CJ, Chen SN, Hwang JF. Intravitreal ranibizumab as salvage therapy in an extremely low‐birth‐weight infant with rush type retinopathy of prematurity. Oman J Ophthalmol 2012; 5: 184–186.
   PubMedGoogle Scholar
• Chen YH, Chen SN, Lien RI et al. Refractive errors after the use of bevacizumab for the treatment of retinopathy of prematurity: 2‐year outcomes. Eye (Lond) 2014; 28: 1080–1086.
   PubMed Web of Science ®Google Scholar
• Milder B. Tropicamide as a cycloplegic agent. Arch Ophthalmol 1961; 66: 70–72.
   PubMedGoogle Scholar
• Lovasik JV. Pharmacokinetics of topically applied cyclopentolate HCl and tropicamide. Am J Optom Physiol Opt 1986; 63: 787–803.
   PubMedGoogle Scholar
• Manny RE, Hussein M, Scheiman M et al. Tropicamide (1%): an effective cycloplegic agent for myopic children. Invest Ophthalmol Vis Sci 2001; 42: 1728–1735.
   PubMed Web of Science ®Google Scholar
• Hamasaki I, Hasebe S, Kimura S et al. Cycloplegic effect of 0.5% tropicamide and 0.5% phenylephrine mixed eye drops: objective assessment in Japanese schoolchildren with myopia. Jpn J Ophthalmol 2007; 51: 111–115.
   PubMed Web of Science ®Google Scholar
• Martinez‐castellanos MA, Schwartz S, Hernandez‐rojas ML et al. Long‐term effect of antiangiogenic therapy for retinopathy of prematurity up to 5-years of follow‐up. Retina 2013; 33: 329–338.
   PubMed Web of Science ®Google Scholar
• Hwang CK, Hubbard GB, Hutchinson AK et al. Outcomes after Intravitreal Bevacizumab versus laser photocoagulation for retinopathy of prematurity: a 5‐year retrospective analysis. Ophthalmology 2015; 122: 1008–1015.
   PubMed Web of Science ®Google Scholar